| Literature DB >> 23209855 |
Debalina Ray1, Tyrrell A Nelson, Chi-Ling Fu, Shailja Patel, Diana N Gong, Justin I Odegaard, Michael H Hsieh.
Abstract
Urogenital schistosomiasis, chronic infection by Schistosoma haematobium, affects 112 million people worldwide. S. haematobium worm oviposition in the bladder wall leads to granulomatous inflammation, fibrosis, and egg expulsion into the urine. Despite the global impact of urogenital schistosomiasis, basic understanding of the associated pathologic mechanisms has been incomplete due to the lack of suitable animal models. We leveraged our recently developed mouse model of urogenital schistosomiasis to perform the first-ever profiling of the early molecular events that occur in the bladder in response to the introduction of S. haematobium eggs. Microarray analysis of bladders revealed rapid, differential transcription of large numbers of genes, peaking three weeks post-egg administration. Many differentially transcribed genes were related to the canonical Type 2 anti-schistosomal immune response, as reflected by the development of egg-based bladder granulomata. Numerous collagen and metalloproteinase genes were differentially transcribed over time, revealing complex remodeling and fibrosis of the bladder that was confirmed by Masson's Trichrome staining. Multiple genes implicated in carcinogenesis pathways, including vascular endothelial growth factor-, oncogene-, and mammary tumor-related genes, were differentially transcribed in egg-injected bladders. Surprisingly, junctional adhesion molecule, claudin and uroplakin genes, key components for maintaining the urothelial barrier, were globally suppressed after bladder exposure to eggs. This occurred in the setting of urothelial hyperplasia and egg shedding in urine. Thus, S. haematobium egg expulsion is associated with intricate modulation of the urothelial barrier on the cellular and molecular level. Taken together, our findings have important implications for understanding host-parasite interactions and carcinogenesis in urogenital schistosomiasis, and may provide clues for novel therapeutic strategies.Entities:
Mesh:
Year: 2012 PMID: 23209855 PMCID: PMC3510078 DOI: 10.1371/journal.pntd.0001912
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Volcano plots of differentially transcribed genes in egg-injected bladders.
Separate plots are shown comparing microarray-derived gene transcription in egg-injected bladders relative to control vehicle-injected bladders (A, one week post-injection; B, three weeks post-injection; C, five weeks post-injection). Log fold changes are plotted on the x-axes and negative log10 p-values are plotted on the y-axes. Red and other non-dark gray, colored symbols denote statistically significant (p<0.05) changes in gene transcription. Gray symbols denote statistically insignificant (p>0.05) changes in change transcription. Legend for individual, selected genes of interest applies to all three panels. For clarity, each selected gene of interest with multiple microarray probes has been denoted using the probe featuring the greatest differential signal for that gene.
Figure 2Real-time PCR corroboration of gene transcription profiles obtained by microarray analysis.
Transcription of a subset of genes analyzed by real-time PCR is depicted in the scatter plots and is displayed as fold change relative to control-injected bladders at 1, 3 and 5 weeks post-injection. Colored bars correspond to microarray data, with decreased, increased, and unchanged transcription colored green, red, and black, respectively. Increasing intensity of green and red bars indicates more extreme changes in transcription (up to >20-fold). * = p<0.05, ** = p<0.01, ***p<0.001 in comparison to control vehicle-injected bladders (or across time points if annotated with brackets). UPK3A: uroplakin 3a, CLDN8: claudin-8, COL4A5: collagen type 4 alpha 5, COL17A1: collagen type 17 alpha 1, NOS2: inducible nitric oxide synthase, UPK3B: uroplakin 3b, UPK1B: uroplakin 1b, UPK1A: uroplakin 1a, UPK2: uroplakin 2, ARG1: arginase-1.
Increased transcription of granulomatous and type 2 inflammation genes identified through microarray analysis.
| Gene | Fold-Regulation Post-Injection Relative to Control | |||
| Time Post-Injection | Week 1 | Week 3 | Week 5 | |
| IL4 |
| 3.48197 | 3.03925 | |
| IL4I1 | 4.62434 | 8.84372 | 9.386889 | |
| IL1B | 6.73795 | 10.05383 |
| |
| IL6 |
| 3.294366 |
| |
| TGFB |
| 2.2158 |
| |
| ARG1 |
| 21.9539 | 7.41649 | |
| CCL4 |
| 3.37419 |
| |
| CCL5 |
|
| 2.605253 | |
| CCL11 |
| 5.88034 | 3.112205 | |
| CXCL1 | 2.27438 | 3.28179 |
| |
| IFI30 |
| 2.545283 | 2.864982 | |
| IFI47 | 2.318303 | 2.252061 |
| |
| IL13RA2 |
| 5.486401 | 3.557954 | |
| IL10RA | 2.014572 | 3.834927 | 3.070781 | |
| CISH |
| 2.600125 |
| |
| ALOX15 |
| 3.397949 | 2.748778 | |
| TBXAS1 | 2.698519 | 2.63449 |
| |
| MPEG1 |
|
| 2.090888 | |
| CHI3L3 |
| 25.39334 | 6.99343 | |
| MRC1 | 2.973735 | 2.644192 |
| |
All values ≥2-fold and p<0.05.
Value <2-fold and/or p≥0.05.
KEGG pathways analysis reveals extensive cytokine-cytokine receptor interactions in the bladder one week post-egg exposure.
| Entrez Gene ID | Gene Name |
| 100048556 | chemokine (C-C motif) ligand 12; similar to MCP-5 |
| 56221 | chemokine (C-C motif) ligand 24 |
| 20306 | chemokine (C-C motif) ligand 7 |
| 20308 | chemokine (C-C motif) ligand 9 |
| 14825 | chemokine (C-X-C motif) ligand 1 |
| 12978 | colony stimulating factor 1 receptor |
| 12984 | CSF 2 receptor, beta 2, low-affinity (granulocyte-macrophage) |
| 16178 | interleukin 1 receptor, type II |
| 16154 | interleukin 10 receptor, alpha |
| 16156 | interleukin 11 |
| 12765 | interleukin 8 receptor, beta |
| 18413 | oncostatin M |
| 12986 | predicted gene 4223; similar to Csf3r protein |
| 100044702 | similar to LPS-induced CXC chemokine; CXCL5 |
| 18383 | TNF receptor superfamily, member 11b (osteoprotegerin) |
All genes shown featured ≥2-fold differential transcription and p<0.05.
KEGG pathways analysis reveals extensive cytokine-cytokine receptor interactions in the bladder three weeks post-egg exposure.
| Entrez Gene ID | Gene Name |
| 21940 | CD27 antigen |
| 21939 | CD40 antigen |
| 20292 | chemokine (C-C motif) ligand 11 |
| 100048556 | chemokine (C-C motif) ligand 12; similar to MCP-5 |
| 18829 | chemokine (C-C motif) ligand 21A |
| 20303 | chemokine (C-C motif) ligand 4 |
| 20306 | chemokine (C-C motif) ligand 7 |
| 20308 | chemokine (C-C motif) ligand 9 |
| 12774 | chemokine (C-C motif) receptor 5 |
| 12458 | chemokine (C-C motif) receptor 6 |
| 12775 | chemokine (C-C motif) receptor 7 |
| 14825 | chemokine (C-X-C motif) ligand 1 |
| 66102 | chemokine (C-X-C motif) ligand 16 |
| 80901 | chemokine (C-X-C motif) receptor 6 |
| 12978 | colony stimulating factor 1 receptor |
| 12984 | CSF 2 receptor, beta 2, low-affinity (granulocyte-macrophage) |
| 12983 | CSF 2 receptor, beta, low-affinity (granulocyte-macrophage) |
| 16323 | inhibin beta-A |
| 16178 | interleukin 1 receptor, type II |
| 16154 | interleukin 10 receptor, alpha |
| 16156 | interleukin 11 |
| 329244 | interleukin 19 |
| 93672 | interleukin 24 |
| 16189 | interleukin 4 receptor, alpha |
| 16190 | interleukin 4 |
| 16193 | interleukin 6 |
| 18053 | nerve growth factor receptor(TNFR superfam., member 16) |
| 18413 | oncostatin M |
| 100041504, 65956 | similar to beta chemokine Exodus-2 |
| 24047 | predicted chemokine (C-C motif) ligand 19 |
| 12986 | similar to Csf3r protein |
| 16186 | predicted interleukin 2 receptor, gamma chain |
| 57349 | pro-platelet basic protein |
| 100044702 | similar to LPS-induced CXC chemokine; CXCL5 |
| 21803 | transforming growth factor, beta 1 |
| 21943 | tumor necrosis factor (ligand) superfamily, member 11 |
| 24099 | tumor necrosis factor (ligand) superfamily, member 13b |
| 72049 | tumor necrosis factor receptor superfamily, member 13c |
| 21935 | tumor necrosis factor receptor superfamily, member 17 |
| 21936 | tumor necrosis factor receptor superfamily, member 18 |
| 22163 | tumor necrosis factor receptor superfamily, member 4 |
All genes shown featured ≥2-fold differential transcription and p<0.05.
KEGG pathways analysis reveals differential transcription of multiple gene members of the B cell receptor pathway five weeks post-egg exposure.
| ENTREZ GENE ID | GENE NAME |
| 17060 | B-cell linker |
| 12229 | Bruton agammaglobulinemia tyrosine kinase |
| 12478 | CD19 antigen |
| 12483 | CD22 antigen; hypothetical protein LOC100047973 |
| 12517 | CD72 antigen |
| 15985 | CD79B antigen |
| 14281 | FBJ osteosarcoma oncogene |
| 14130 | Fc receptor, IgG, low affinity IIb |
| 240168 | RAS, guanyl releasing protein 3 |
| 19354 | RAS-related C3 botulinum substrate 2 |
| 108723 | caspase recruitment domain family, member 11 |
| 12902 | complement receptor 2 |
| 380794 | immunoglobulin heavy chain 3 (serum IgG2b); Ig heavy chain (gamma polypeptide) |
| 16331 | inositol polyphosphate-5-phosphatase D |
| 68713 | interferon induced transmembrane protein 1 |
| 240354 | mucosa associated lymphoid tissue lymphoma translocation gene 1 |
| 18018 | nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 |
| 18037 | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon |
| 18707 | phosphatidylinositol 3-kinase catalytic delta polypeptide; RIKEN cDNA 2610208K16 gene |
| 83490 | phosphoinositide-3-kinase adaptor protein 1 |
| 30955 | phosphoinositide-3-kinase, catalytic, gamma polypeptide |
| 234779 | phospholipase C, gamma 2 |
| 16061 | predicted immunoglobulin heavy chain (J558 family) |
| 19057 | protein phosphatase 3, catalytic subunit, gamma isoform |
| 15170 | protein tyrosine phosphatase, non-receptor type 6 |
| 22324 | vav 1 oncogene |
All genes shown featured ≥2-fold differential transcription and p<0.05.
Figure 3Bladder wall injection with S. haematobium eggs triggers granuloma growth and urothelial hyperplasia.
Intramural injection of S. haematobium eggs results in granuloma development. A, micro-ultrasonography of a single representative animal injected with control vehicle showing no granuloma formation; B, micro-ultrasonography of a single representative animal injected with eggs, note the presence of a bright, echogenic round granuloma (denoted by white arrow). Intramural injection of S. haematobium eggs initiates histologically-evident granuloma formation by one week and persisting for over five weeks (D–F), while control vehicle injection does not result in granuloma formation (C). Intramural injection of S. haematobium eggs induces early and sustained urothelial hyperplasia with reactive nuclear changes (1, 3, and 5 weeks post-injection, H–J), whereas control vehicle injected-bladders feature normal appearing urothelium (G). Arginase-1-specific immunohistochemistry confirms widespread expression of the enzyme in the bladder 4 weeks post-egg injection (K).
Microarray analysis reveals urothelial barrier function genes with less transcription after egg exposure.
| Gene | Fold-Regulation Post-Injection Relative to Control | |||
| Time Post-Injection | Week 1 | Week 3 | Week 5 | |
| UPK2 |
| 0.19028 | 0.303506 | |
| UPK1A |
| 0.155542 | 0.311607 | |
| UPK1B |
| 0.262438 |
| |
| UPK3A |
| 0.159784 | 0.320718 | |
| UPK3B |
| 0.281346 | 0.376946 | |
| CLDN8 |
| 0.398229 |
| |
| CLDN10 |
| 0.448328 | 0.46717 | |
| CLDN23 |
| 0.48318 | 0.495167 | |
| JAM4 |
| 0.374898 | 0.446032 | |
All values shown ≥2-fold and p<0.05.
Value <2-fold and/or p≥0.05.
Figure 4S. haematobium eggs are shed in the urine of bladder wall-injected mice.
Micrograph showing two intact S. haematobium eggs isolated from the urine of a bladder wall-injected mouse 2 weeks post-egg injection.
Pathways analysis reveals differential transcription of multiple gene members of the vascular endothelial growth factor-related pathway five weeks post-egg exposure.
| ENTREZ GENE ID | GENE NAME |
| 19354 | RAS-related C3 botulinum substrate 2 |
| 27371 | SH2 domain protein 2A |
| 15507 | heat shock protein 1 |
| 18018 | nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 |
| 18707 | phosphatidylinositol 3-kinase catalytic delta polypeptide; RIKEN cDNA 2610208K16 gene |
| 30955 | phosphoinositide-3-kinase, catalytic, gamma polypeptide |
| 234779 | phospholipase C, gamma 2 |
| 19057 | protein phosphatase 3, catalytic subunit, gamma isoform |
All genes shown featured ≥2-fold differential transcription and p<0.05.
Pathways analysis reveals differential transcription of multiple gene members of oncogene-related pathways five weeks post-egg exposure.
| ENTREZ GENE ID | GENE NAME |
| 12143 | B lymphoid kinase |
| 66813 | BCL2-like 14 (apoptosis facilitator) |
| 14281 | FBJ osteosarcoma oncogene |
| 14191 | Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog |
| 16909 | LIM domain only 2 |
| 14159 | feline sarcoma oncogene |
| 17095 | lymphoblastomic leukemia 1 |
| 16818 | lymphocyte protein tyrosine kinase |
| 20423 | sonic hedgehog |
| 22324 | vav 1 oncogene |
All genes shown feature ≥2-fold differential transcription and p<0.05.
Pathways analysis reveals differential transcription of multiple gene members of mammary carcinogenesis-related pathways five weeks post-egg exposure.
| ENTREZ GENE ID | GENE NAME |
| 23960 | 2′-5′ oligoadenylate synthetase 1G |
| 53313 | ATPase, Ca++ transporting, ubiquitous |
| 140703 | EMI domain containing 1 |
| 246256 | Fc receptor, IgG, low affinity IV |
| 18194 | NAD(P) dependent steroid dehydrogenase-like |
| 18104 | NAD(P)H dehydrogenase, quinone 1 |
| 229003 | cDNA sequence BC006779 |
| 13040 | cathepsin S |
| 58187 | claudin 10 |
| 12262 | complement component 1, q subcomponent, C chain |
| 93726 | eosinophil-associated, ribonuclease A family, member 11 |
| 235439 | hect domain and RCC1 (CHC1)-like domain (RLD) 1 |
| 14960, 14968 | histocompatibility 2, class II antigen A/E alpha |
| 14998 | histocompatibility 2, class II, locus DMa |
| 14999 | histocompatibility 2, class II, locus Mb1 |
| 380794 | Ig heavy chain 3 (serum IgG2b); Ig heavy chain (gamma polypeptide) |
| 15894 | intercellular adhesion molecule 1 |
| 68713 | interferon induced transmembrane protein 1 |
| 107321 | leupaxin |
| 109225 | membrane-spanning 4-domains, subfamily A, member 7 |
| 17969 | neutrophil cytosolic factor 1 |
| 545007, 545013, 100040671 | alpha7-takusan |
| 16061, 100048770 | immunoglobulin heavy chain (J558 family) |
| 19283 | protein tyrosine phosphatase, receptor type Z, polypeptide 1 |
| 20345 | selectin, platelet (p-selectin) ligand |
| 19261 | signal-regulatory protein alpha |
| 100044683 | Leucine rich repeat containing 8 family, member E |
| 100047788 | similar to gamma-2a immunoglobulin heavy chain |
| 100047619 | similar to solute carrier family 7 (y+ system), member 5 |
| 21753 | testis derived transcript |
| 17230 | tryptase alpha/beta 1 |
All genes shown feature ≥2-fold differential transcription and p<0.05.
Extracellular matrix-related genes featuring altered transcription by microarray analysis.
| Gene | Fold-Regulation Post-Injection Relative to Control | |||
| Time Post-Injection | Week 1 | Week 3 | Week 5 | |
| COL3A1 |
| 0.302919 | 0.258949 | |
| COL4A5 |
| 0.437578 |
| |
| COL6A3 |
| 0.448199 |
| |
| COL8A2 |
| 0.457323 |
| |
| COL17A1 |
| 3.59083 | 3.392723 | |
| COL7A1 |
| 2.00841 | 2.16737 | |
| TIMP1 | 6.01549 | 7.713105 | 3.41333 | |
| MMP10 | 8.79182 | 18.2758 | 11.5372 | |
| MMP13 | 4.98769 | 16.2878 | 5.75328 | |
| MMP3 | 2.21056 | 3.203963 | 3.084574 | |
| MMP9 |
| 3.90035 |
| |
All values shown ≥2-fold and p<0.05 unless otherwise noted.
Value <2-fold and/or p≥0.05.
Figure 5S. haematobium egg-injected bladders develop fibrosis.
Egg-injected bladders demonstrate histologically-apparent fibrosis within granulomata (right column, sections from week 3 post-egg injection bladder, Masson's Trichrome stain, collagen stains blue; left column, sections from week 3 post-control vehicle injection bladder show no granuloma and normal collagen staining pattern).